Lower pricing structures for oral weight-loss medications from Novo Nordisk and Eli Lilly are increasingly motivating patients to transition away from compounded drugs toward authentic branded options. Historically, the rampant shortages of branded injectable obesity treatments allowed compounding pharmacies to flourish by mixing their own personalized formulations.
